Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, ...

Boston Scientific has claimed a new approval from the FDA for its Farapulse pulsed field ablation system, expanding its use ...

The FARAPULSE PFA System now approved for pulmonary vein and posterior wall ablation in patients with persistent atrial ...

The funding will allow the Canadian company to pursue regulatory approvals and build up its manufacturing capabilities and ...

Boston Scientific (NYSE: BSX) announced that the FDA approved an expansion to the label of its Farapulse pulsed field ...

On the heels of the first pulsed-field ablation device to win approval for atrial fibrillation ablation, a novel version of ...

Boston Scientific Corp. gained a second U.S. FDA approval for its Farapulse pulsed field ablation catheter, expanding its use into drug-refractory, symptomatic persistent atrial fibrillation (AF) in ...

Boston Scientific (NYSE:BSX) recently achieved FDA approval to expand the FARAPULSE™ Pulsed Field Ablation (PFA) System's use, enhancing treatment options for persistent atrial fibrillation. This ...

The pulsed field ablation developer Kardium has collected $250 million in funding to gear up for the commercial expansion of ...

Kardium announced today that it raised $250 million in a new financing round to support the launch of its pulsed field ...

The funding will support the launch of the VERITAS trial while strengthening the company's clinical and regulatory ...

The medtech startup founded by physician and Farapulse inventor Steven Mickelsen is preparing to begin a pivotal study of ...